Last reviewed · How we verify
NCT07480317: PD TIS
TIS for Brain Network Modulation and Clinical Efficacy in Parkinson's Disease
NA trial testing Temporal Interference Stimulation (130 Hz) in PARKINSON DISEASE (Disorder) in 75 participants. Not yet recruiting.
31 August 2026
Quick facts
| Lead sponsor | Jiangsu Province Nanjing Brain Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 20 March 2026 |
| Primary completion | 31 August 2026 |
| Estimated completion | 31 March 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Temporal Interference Stimulation (130 Hz)
- Temporal Interference Stimulation (40 Hz)
- Sham Temporal Interference Stimulation
Conditions studied
- PARKINSON DISEASE (Disorder) — all drugs for PARKINSON DISEASE (Disorder) →
Sponsor
Jiangsu Province Nanjing Brain Hospital
Who can join
Adults 45 to 65, any sex, with PARKINSON DISEASE (Disorder). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction. While deep brain stimulation (DBS) is effective, its invasive nature limits its application in early-stage patients. Temporal interference stimulation (TIS) is a novel non-invasive technique that can target deep brain structures like the globus pallidus internus (GPi) by using high-frequency electric fields. This study aims to evaluate the clinical value and underlying mechanisms of TIS in PD patients. The research is divided into two phases: Phase A investigates the immediate regulatory effects of 130 Hz and 40 Hz TIS on brain networks using concurrent fMRI-TIS. Phase B is a randomized, double-blind, sham-controlled trial to assess the long-term efficacy and safety of a 2-week TIS intervention on both motor and non-motor symptoms. The results will help clarify how TIS modulates deep brain networks and its potential as a non-invasive therapy for PD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07480317
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for PARKINSON DISEASE (Disorder)
Currently open trials in the same condition.
- NCT07519096 — Steady Together Fall Prevention Program in the Home · NA · recruiting
- NCT07518290 — Remotely Supervised Home-based Transcranial Temporal Interference Stimulation on Motor Symptoms in Parkinson's Disease · NA · recruiting
- NCT07498296 — Adapting rHIRE and Sleep Monitoring in Parkinson's Disease · NA · recruiting
- NCT07478146 — Brief Title: Aerobic Training on Cerebrovascular Function, Cognition and Gait in Parkinson's Disease · NA · recruiting
- NCT07467460 — Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disea · recruiting
Other Jiangsu Province Nanjing Brain Hospital trials
Trials by the same sponsor.
- NCT07317557 — Remote Ischemic Conditioning for Cognitive Impairment in Cerebral Small Vessel Disease · NA · not yet recruiting
- NCT07323121 — 40 Hz Flickering for Insomnia in Parkinson's Disease · NA · not yet recruiting
- NCT07299240 — Remote Ischemic Conditioning for Sleep Disturbances and Other Non-motor Symptoms in Parkinson's Disease · NA · not yet recruiting
- NCT07492472 — The Effects of Low-Intensity Music in Adolescents With Anxiety · NA · recruiting
- NCT07246044 — HD-tDCS for Adolescent Bipolar Depression Targeting S1 · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07480317 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu Province Nanjing Brain Hospital
- Last refreshed: 24 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07480317.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing